The Committee on Infectious Diseases of the American Academy of Pediatrics attempts to provide "guidelines that complement the physician's clinical judgment and facilitate the making of well reasoned decisions. Unanswered scientific questions, the complexity of medical practice, new information, and inevitable differences of opinion between experts result in inherent limitations"1 in this process.

With regard to the first-generation Haemophilus b polysaccharide vaccines (HBPV or PRP), the Committee issued a statement on Nov 13, 1987 (PedComm: AAP Member Alert), in which its concern regarding the preliminary efficacy estimates derived from "case-control" studies performed by several investigative groups in various areas in the United States was expressed.

This content is only available via PDF.
You do not currently have access to this content.